EPITHELICA
Precision gene therapies for epithelial diseases
Epithelica develops safe, non-viral gene therapies for severe genetic skin and other epithelial disorders, aiming to restore healthy tissue and transform everyday life for patients and families.
Our Mission
To create accessible, one-time gene therapies that offer durable benefit and real hope to underserved patients living with serious genetic epithelial diseases.
Our Solution
non-viral, mutation-targeted gene editing platform delivered by topical lipid nanoparticles to correct disease-causing mutations directly in epithelial tissues.
Key facts about our solution
Why our approach is unique
Precisely targeted
Designed to reach affected skin cells and address the underlying genetic error for deep and lasting improvement, not just symptom relief.
Built around patient needs
Focused on severe, underserved rare skin diseases where current options are limited or purely symptomatic.
Non-invasive delivery
Uses advanced gene editing tools with topical, non-viral formulations to support safety, comfort, and ease of use for patients and clinicians.
Partner with Us
How to collaborate
Work with Epithelica to accelerate new therapies for genetic epithelial diseases and expand next-generation dermatology pipelines.
Gene therapy development
Joint programs for next-generation therapies in severe genetic skin diseases.
Technology licensing
Access to proprietary non-viral gene editing and topical LNP delivery platforms.
Scientific consulting
Expertise in gene therapy design, preclinical strategy, and clinical translation in dermatology.
Ready to make a difference?
- Patients & Families: Learn more about how future Epithelica therapies could address the root cause of certain genetic skin and epithelial diseases.
- Investors & Partners: Explore collaboration, licensing, and investment opportunities in our precision gene therapy platform.
Reach out today
Email: [email protected]